Azathioprine or 6‐mercaptopurine showed no clear difference in maintenance of remission compared with mesalazine or sulfasalazine (low certainty).
It is very uncertain whether azathioprine or 6‐mercaptopurine changes adverse events compared with mesalazine or sulfasalazine (very low certainty).
It is very uncertain whether azathioprine or 6‐mercaptopurine changes withdrawals due to adverse events compared with mesalazine or sulfasalazine (very low certainty).
It is very uncertain whether azathioprine or 6‐mercaptopurine changes serious adverse events compared with mesalazine or sulfasalazine (very low certainty).
It is very uncertain whether budesonide 6‐9 mg changes continued remission at 12 months compared with azathioprine 2‐2.5 mg/kg (very low certainty).
It is very uncertain whether methotrexate changes adverse events (Ardizzone 2003) compared with 6‐MP or azathioprine (very low certainty).
It is very uncertain whether methotrexate changes withdrawal due to adverse event (Oren 1997) compared with 6‐MP or azathioprine (very low certainty).
Methotrexate showed no clear difference in failure to enter remission or possible remission at 24‐36 weeks… compared with 6‐MP or azathioprine (low certainty).
It is very uncertain whether the intervention changes acute pancreatitis (very low certainty).
It is very uncertain whether the intervention changes bone marrow suppression (very low certainty).
It is very uncertain whether 6‐Mercaptopurine changes failure to maintain remission compared with 5‐ASA (very low certainty).
It is very uncertain whether 6‐Mercaptopurine changes failure to maintain remission compared with methotrexate (very low certainty).
It is very uncertain whether the intervention changes any adverse event (very low certainty).
It is very uncertain whether the intervention changes withdrawal due to adverse event (very low certainty).
It is very uncertain whether 6‐Mercaptopurine changes maintenance of remission compared with methotrexate (very low certainty).
It is very uncertain whether 6‐Mercaptopurine changes adverse events compared with methotrexate (very low certainty).
It is very uncertain whether 6‐Mercaptopurine changes withdrawals due to adverse events compared with methotrexate (very low certainty).
It is very uncertain whether 6‐Mercaptopurine changes serious adverse events compared with methotrexate (very low certainty).